Core Viewpoint - The company has announced its third-quarter financial report, emphasizing the accuracy and completeness of the information provided by its board and management, while also detailing its share repurchase plan and ongoing legal issues related to a fraud case [2][6][7]. Financial Data - The financial report for the third quarter is unaudited, and the company has provided key financial data and indicators in RMB [3][8]. - As of September 30, 2025, the company has repurchased a total of 2,005,500 shares, with a total expenditure of 12.089 million RMB (excluding transaction fees) [7]. Share Repurchase Plan - The company plans to repurchase shares using its own funds through centralized bidding, with a maximum price of 10.00 RMB per share and a total repurchase amount between 100 million RMB and 200 million RMB, to be completed within 12 months from the board's approval [6][7]. Legal Issues - The company is currently facing 14 lawsuits from primary distributors involving a total of 69.5026 million RMB, and 10 lawsuits from secondary distributors involving 17.0766 million RMB, related to a case of forgery involving a former employee [7].

（编辑 姚尧） 证券日报网讯 10月31日晚间，济民健康发布公告称，公司于近日收到双鸽集团有限公司（以下简称"双 鸽集团"）通知，双鸽集团在浙商银行股份有限公司台州分行质押的17，640，000股股份办理了解除质 押手续。 ...

Core Points - Jimin Health announced that it will not implement a share buyback in October 2025 [2] Group 1 - The company released an announcement on October 31 regarding its decision on share repurchase [2]

Group 1 - The core point of the news is that Jimin Health (SH 603222) announced the release of 17.64 million shares from pledge by its major shareholder, Shuangge Group, which holds approximately 123 million shares, accounting for 23.38% of the total share capital [1] - After the release of the pledge, Shuangge Group has a total of 76.5 million shares pledged, which is 62.32% of its holdings and 14.57% of the total share capital [1] - The combined shareholding of Shuangge Group and its concerted parties is about 229 million shares, representing 43.52% of the total share capital [1] Group 2 - As of the announcement, Jimin Health's market capitalization is 5.4 billion yuan [2] - For the first half of 2025, Jimin Health's revenue composition is as follows: 52.07% from the pharmaceutical manufacturing sector, 46.01% from the medical services sector, 1.54% from pharmaceutical trading, and 0.38% from other businesses [1]

证券代码：603222 证券简称：济民健康 公告编号：2025-050 济民健康管理股份有限公司 关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 双鸽集团持有公司股份数量为 122,748,520 股，占公司总股本的 23.38%。 本次解除质押数量为 17,640,000 股，截止本次解质完成，双鸽集团累计质押股 份数量为76,500,000股，占其所持股份数量比例62.32%，占公司总股本的14.57%。 ● 双鸽集团及其一致行动人合计持有公司股份 228,557,540 股，占公司总 股本的 43.52%。本次股份解除质押后，控股股东及其一致行动人累计质押股份 140,900,000 股，占其所持股份的 61.65%，占公司总股本的 26.83%。 公司于近日收到双鸽集团有限公司（以下简称"双鸽集团"）通知，双鸽集 团在浙商银行股份有限公司台州分行质押的 17,640,000 股股份办理了解除质押 手续，具体情况如下： 济民健康管理股份有限公司董事会 | 股东名称 ...

证券代码：603222 证券简称：济民健康 公告编号：2025-051 济民健康管理股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | 累计已回购股数 | 200.55万股 | | 累计已回购股数占总股本比例 | 0.38% | | 累计已回购金额 | 1,208.9万元 | | 实际回购价格区间 | 5.87元/股~6.13元/股 | 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况 ...

Core Viewpoint - Jimin Health announced the release of 17.64 million shares pledged by Shuangge Group, which represents 14.37% of Shuangge's holdings and 3.36% of the company's total share capital [1] Group 1: Share Pledge Details - The release of the pledged shares occurred on October 30, 2025 [1] - After the release, Shuangge Group has a total of 76.50 million shares pledged, accounting for 62.32% of its holdings and 14.57% of the company's total share capital [1] - As of the announcement date, the controlling shareholder and its concerted parties hold a total of 228.56 million shares, with 14.09 million shares pledged, which is 61.65% of their holdings and 26.83% of the company's total share capital [1]

Core Viewpoint - The company announced a share repurchase plan with a budget of 100-200 million yuan, aimed at employee stock ownership plans or equity incentives, with a duration of 12 months from board approval [1] Group 1: Share Repurchase Details - The company plans to repurchase shares through centralized bidding starting from March 28, 2025 [1] - As of October 31, 2025, the company has repurchased a total of 2.0055 million shares, accounting for 0.38% of the total share capital [1] - The total amount spent on the repurchase is 12.089 million yuan, with a repurchase price range of 5.87-6.13 yuan per share [1] Group 2: Implementation Status - As of October 2025, the company has not implemented any further repurchase actions [1]

Core Viewpoint - Jimin Health (603222.SH) announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Summary by Categories Share Buyback Details - As of October 31, 2025, the company has repurchased a total of 2.0055 million shares, which represents 0.3819% of the total share capital [1] - The highest purchase price for the shares was 6.13 CNY per share, while the lowest was 5.87 CNY per share [1] - The total amount spent on the buyback, excluding transaction fees, was 12.089 million CNY [1]

Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]